SCHEMBL3013763

SCHEMBL3013763

CCOc1ccc(-c2csc(N3CCC(S(=O)(=O)c4ccccc4C#N)CC3)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.46
LMNA P02545 6/20 0.46
MAPK1 P28482 5/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
SMN1; SMN2 Q16637 7/20 0.44
RAB9A P51151 5/20 0.44
NPC1 O15118 4/20 0.43
ALDH1A1 P00352 3/20 0.43
DRD2 P14416 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
KCNH2 Q12809 1/20 0.41
TSHR P16473 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
HTT P42858 1/20 0.40
CTSS P25774 2/20 0.40
RET P07949 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016406 0.90 MAPT (0.58) MAPTLMNAMAPK1MEN1KMT2A
SCHEMBL3015187 0.89 KMT2A (0.48) MAPTLMNAMAPK1MEN1KMT2A
SCHEMBL3017477 0.87 SMN1; SMN2 (0.53) MAPTLMNAMAPK1MEN1KMT2A
SCHEMBL3011288 0.87 LMNA (0.52) MAPTLMNAMAPK1MEN1KMT2A
SCHEMBL3005312 0.87 KMT2A (0.47) MAPTLMNAMAPK1MEN1KMT2A
SCHEMBL3020092 0.87 MAPT (0.48) MAPTLMNAMAPK1MEN1KMT2A
SCHEMBL3019047 0.87 MAPT (0.48) MAPTLMNAMAPK1MEN1KMT2A
SCHEMBL3015118 0.86 DRD2 (0.40) MAPTDRD2HTR2AHTR2CKCNH2
SCHEMBL3011980 0.86 LMNA (0.55) MAPTLMNAMAPK1MEN1KMT2A
SCHEMBL3014741 0.86 MAPT (0.52) MAPTLMNAMAPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885LMNA 80/4885MAPK1 2767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.